Zynerba Stock Today

ZYNE
 Stock
  

USD 1.15  0.08  6.50%   

Market Performance
0 of 100
Odds Of Distress
Less than 6
Zynerba Pharma is trading at 1.15 as of the 29th of June 2022, a -6.5 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.13. Zynerba Pharma has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Zynerba Pharma CS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of July 2020 and ending today, the 29th of June 2022. Click here to learn more.
CUSIP
98986X109
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
5th of August 2015
Category
Healthcare
Classification
Health Care
ISIN
US98986X1090
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 41.22 M outstanding shares of which 1.35 M shares are at this time shorted by private and institutional investors with about 4.85 trading days to cover. More on Zynerba Pharma CS

Moving together with Zynerba Pharma

0.65JPMJP Morgan Chase Earnings Call  In Two WeeksPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Zynerba Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Zynerba Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Zynerba Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Zynerba Pharma CS generated a negative expected return over the last 90 days
Zynerba Pharma CS has high historical volatility and very poor performance
Zynerba Pharma CS may become a speculative penny stock
The company reported the previous year's revenue of 86 K. Net Loss for the year was (37.31 M) with profit before overhead, payroll, taxes, and interest of 86 K.
Zynerba Pharma CS currently holds about 67.81 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Zynerba Pharma CS has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Brian Rosenberger of 48000 shares of Zynerba Pharma subject to Rule 16b-3
Chairman and CEOArmando Anido
Average Analyst Recommendation
Analysts covering Zynerba Pharma report their recommendations after researching Zynerba Pharma's financial statements, talking to executives and customers, or listening in on Zynerba Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Zynerba Pharma CS. The Zynerba consensus assessment is calculated by taking the average forecast from all of the analysts covering Zynerba Pharma.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Zynerba Pharma CS based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Zynerba Pharma CS financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares42.4 M39.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted42.4 M39.3 M
Significantly Up
Increasing
Slightly volatile
Total Assets64.9 M81.2 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities8.7 M10.3 M
Fairly Down
Increasing
Slightly volatile
Current Assets64.1 M80.2 M
Significantly Down
Increasing
Slightly volatile
Current Liabilities8.4 M9.9 M
Fairly Down
Increasing
Slightly volatile
Total Debt447.4 K450 K
Slightly Down
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.00150.0014
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Zynerba Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Zynerba Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Zynerba Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zynerba Pharma's financial leverage. It provides some insight into what part of Zynerba Pharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Zynerba Pharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Zynerba Pharma deploys its capital and how much of that capital is borrowed.
Liquidity
Zynerba Pharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 562.76 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Zynerba Pharma CS has a current ratio of 7.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Zynerba Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Zynerba Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zynerba Pharma CS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zynerba to invest in growth at high rates of return. When we think about Zynerba Pharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(36.1 Million)Share
Zynerba Pharma CS (ZYNE) is traded on NASDAQ Exchange in USA and employs 28 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 51.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zynerba Pharma's market, we take the total number of its shares issued and multiply it by Zynerba Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Zynerba Pharma CS conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 41.22 M outstanding shares of which 1.35 M shares are at this time shorted by private and institutional investors with about 4.85 trading days to cover. Zynerba Pharma CS currently holds about 67.81 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Zynerba Pharma Probability Of Bankruptcy
Ownership
Zynerba Pharma CS owns a total of 41.22 Million outstanding shares. 30% of Zynerba Pharma outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Zynerba Ownership Details

Zynerba Stock Price Odds Analysis

What are Zynerba Pharma's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Zynerba Pharma jumping above the current price in 90 days from now is about 68.69%. The Zynerba Pharma CS probability density function shows the probability of Zynerba Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3841. This usually means as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Zynerba Pharma will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Zynerba Pharma CS is significantly underperforming DOW.
  Odds Below 1.15HorizonTargetOdds Above 1.15
31.24%90 days
 1.15 
68.69%
Based on a normal probability distribution, the odds of Zynerba Pharma to move above the current price in 90 days from now is about 68.69 (This Zynerba Pharma CS probability density function shows the probability of Zynerba Stock to fall within a particular range of prices over 90 days) .

Zynerba Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Zynerba Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Zynerba Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Zynerba Pharma's value.
InstituionSecurity TypeTotal SharesValue
Etf Managers Group LlcCommon Shares3.7 M7.9 M
Vanguard Group IncCommon Shares1.9 MM
View Zynerba Pharma Diagnostics

Zynerba Pharma Historical Income Statement

Zynerba Pharma CS Income Statement is one of the three primary financial statements used for reporting Zynerba's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Zynerba Pharma CS revenue and expense. Zynerba Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Zynerba Pharma Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 11.53 Million. The current year Revenues is expected to grow to about 101.5 K, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to (14.8 M). View More Fundamentals

Zynerba Stock Against Markets

Picking the right benchmark for Zynerba Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Zynerba Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Zynerba Pharma is critical whether you are bullish or bearish towards Zynerba Pharma CS at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Zynerba Pharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now

   

Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Zynerba Pharma Corporate Directors

Zynerba Pharma corporate directors refer to members of a Zynerba Pharma board of directors. The board of directors generally takes responsibility for the Zynerba Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Zynerba Pharma's board members must vote for the resolution. The Zynerba Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Daniel Kisner - Director NomineeProfile
William Federici - Director NomineeProfile
Kenneth Moch - Director NomineeProfile
Thomas Harrison - Director NomineeProfile

Investing Zynerba Pharma CS

You need to understand the risk of investing before taking a position in Zynerba Pharma. The danger of trading Zynerba Pharma CS is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zynerba Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zynerba Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zynerba Pharma CS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Your Current Watchlist. Note that the Zynerba Pharma CS information on this page should be used as a complementary analysis to other Zynerba Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Zynerba Stock analysis

When running Zynerba Pharma CS price analysis, check to measure Zynerba Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zynerba Pharma is operating at the current time. Most of Zynerba Pharma's value examination focuses on studying past and present price action to predict the probability of Zynerba Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zynerba Pharma's price. Additionally, you may evaluate how the addition of Zynerba Pharma to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Zynerba Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zynerba Pharma. If investors know Zynerba will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zynerba Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
50.9 M
Return On Assets
-0.26
Return On Equity
-0.47
The market value of Zynerba Pharma CS is measured differently than its book value, which is the value of Zynerba that is recorded on the company's balance sheet. Investors also form their own opinion of Zynerba Pharma's value that differs from its market value or its book value, called intrinsic value, which is Zynerba Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zynerba Pharma's market value can be influenced by many factors that don't directly affect Zynerba Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zynerba Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Zynerba Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zynerba Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.